169 related articles for article (PubMed ID: 31764020)
1. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma.
Marks EI; Brown VS; Dizon DS
Am J Clin Oncol; 2020 Feb; 43(2):139-145. PubMed ID: 31764020
[TBL] [Abstract][Full Text] [Related]
2. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
4. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
7. Personalized therapy in gynecological cancer: a reality in clinical practice?
Banerjee S; Gore M
Curr Oncol Rep; 2013 Jun; 15(3):201-3. PubMed ID: 23532395
[No Abstract] [Full Text] [Related]
8. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.
Oda K; Ikeda Y; Kashiyama T; Miyasaka A; Inaba K; Fukuda T; Asada K; Sone K; Wada-Hiraike O; Kawana K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2016 Jul; 42(7):757-62. PubMed ID: 27094348
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):847-58. PubMed ID: 25301678
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
Chua W; Moore MM; Charles KA; Clarke SJ
Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
Itamochi H; Oishi T; Oumi N; Takeuchi S; Yoshihara K; Mikami M; Yaegashi N; Terao Y; Takehara K; Ushijima K; Watari H; Aoki D; Kimura T; Nakamura T; Yokoyama Y; Kigawa J; Sugiyama T
Br J Cancer; 2017 Aug; 117(5):717-724. PubMed ID: 28728166
[TBL] [Abstract][Full Text] [Related]
12. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract][Full Text] [Related]
14. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
15. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
[TBL] [Abstract][Full Text] [Related]
16. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
18. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
